Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q3 2022 · 10-Q
Revenue$0.00$0.00— vs Q3 2021 Net Income-$681.65K-$681.65KN/M vs Q3 2021 EPS Diluted-$0.05-$0.05N/M vs Q3 2021 Operating Income-$635,006N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
derived
ended May 31, 2022 · filed Jul 14, 2022 · 44 d after period end